STOCKHOLM, Sweden, February 24, 2026. KDventures AB (Nasdaq Stockholm: KDV) announces that the planned reversed acquisition of the portfolio company SVF Vaccines by Novakand Pharma will not be completed, following Nasdaq’s rejection of an application for continued listing of the combined entity. On February 6, 2026, it was announced that KDventures and the other shareholders of SVF Vaccines had entered into an acquisition agreement with Novakand Pharma regarding a reverse acquisition of SVF Vaccines. Comple ...